In our presentation today, we will unravel the transformative power of vaccines in women, aligning with the Sustainable Development Goals (SDGs) for 2030. By exploring the pivotal role of vaccinations, we aim to elucidate how they contribute to women's health, empowerment, and overall well-being. Through this lens, we envision a future where widespread vaccine access propels us closer to achieving the SDGs and ensures a healthier, more equitable world for women globally.

1. VACCINE IN WOMEN TOWARDS
SUSTAINABLE DEVELOPMENT GOALS
2030

2. Name : Dr. Niranjan Chavan
MBBS, MD, FCPS, DGO, MICOG, DICOG,
FICOG, DFP, DIPLOMA IN ENDOSCOPY(USA)
Affiliation :Professor (Full) and Unit Chief,
L.T.M.M.C & L.T.M.G.H, Sion Hospital
Joint Treasurer, FOGSI (2021-2025)
President, MOGS (2022-2023)
Organising Secretary, AICOG, Mumbai 2025,
Treasurer, AFG (2023-2024)
Title : Vaccination in Women Towards SDG 2030
City : Mumbai
Your Photo

3. OVERVIEW
• HISTORY
• INTRODUCTION
• TARGETS
• VISION & IMPACT GOALS
• STRATEGIC PRIORITIES
• CORE PRINCIPLES
• INTER-RELATION OF IMMUNIZATION WITH
SUSTAINABLE DEVELOPMENT GOALS
• HPV VACCINE
• COVID-19 VACCINE IN PREGNANCY
• REFERENCES

8. INTRODUCTION
• The Immunization Agenda 2030
(IA2030) is an ambitious global strategy
to maximize the lifesaving impact of
vaccines that, if fully implemented, will
save 50 million lives over the next decade.
(2021-2030)
• The vision for the decade is: A world
where everyone, everywhere, at every age,
fully benefits from vaccines for good health
and well-being.

9. THE TARGETS
1. Achieving 90% coverage for essential
vaccines given in childhood and
adolescence
2. Halving the number of children
completely missing out on vaccines

10. 3. Completing 500 introductions of new or
under-utilized vaccines - such as those for
COVID-19, rotavirus, or human
papillomavirus (HPV).

11. VISION & IMPACT GOALS

12. STRATEGIC PRIORITIES

13. 4 CORE PRINCIPLES OF IA 2030
The design, management, and delivery of immunization services
should be shaped by and responsive to the needs of individuals and
communities, including addressing barriers to access to immunization
services due to age, location, social and cultural norms, and gender-
related factors.
Countries should establish targets that represent the local context
and should be held accountable for achieving them.

14. Immunization partners should align and coordinate their actions to
increase efficiency, build on complementarity, and involve sectors
beyond immunization for mutual benefit.
Promoting evidence-based decision-making. High-quality, “fit-for-
purpose” data will be used to track progress, improve program
performance and form the basis of decision-making at all levels.

15. CONTRIBUTIONS AND RELEVANCE OF
IMMUNIZATION TO 14 OF THE 17 SDGS
(SUSTAINABLE DEVELOPMENT GOALS)

16. VACCINE RELATED TO WOMEN IN
IMMUNIZATION AGENDA 2030
1. HUMAN PAPILLOMAVIRUS
VACCINE
• Cervical cancer is the fourth most common
cancer in women globally with an estimated
6,04,000 new cases and 3,42,000 deaths in
2020.

17. VACCINE TYPES & SCHEDULE
• There are six licensed HPV vaccines: three bivalent, two
quadrivalent, and one nona-valent vaccine.
• The primary target group in most of the countries
recommending HPV vaccination is young adolescent girls,
aged 9-14. As per the December 2022 WHO Position on HPV
vaccines, WHO recommends the following schedule:
•A one or two-dose schedule for girls aged 9-14
•A one or two-dose schedule for girls and women aged 15-20
•Two doses with a 6-month interval for women older than 21
• A minimum of 2 doses and when feasible 3-doses remain
necessary for those known to be immunocompromised and/or
HIV-infected.

18. • In countries that have introduced the vaccine against
human papillomavirus (HPV), after 5–8 years,
cancer-causing HPV prevalence was reduced by
83% among girls aged 13–19, and the prevalence of
precancerous lesions decreased by 51% among girls
aged 15–19.

19. The WHO Global Strategy defines elimination as reducing the number of
new cases annually to 4 or fewer per 100 000 women and sets three targets to
be achieved by the year 2030 to put all countries on the pathway to
elimination in the coming decades:
•90% of girls vaccinated with the HPV vaccine by age 15
•70% of women screened with a high-quality test by ages 35 and 45
•90% of women with cervical disease receive treatment
Modeling estimates that 74 million new cases of cervical cancer can be
averted, and 62 million deaths can be avoided by reaching this elimination
goal.

22. 2. COVID-19 VACCINE IN PREGNANCY
• The Ministry of Health and Family Welfare, Government of India,
approved the vaccination of pregnant women against COVID-19 on 2nd July
2021.
• Protective antibodies are found in umbilical cord blood and breast milk which
shows protection to the neonate.

24. FIGO STATEMENT ON COVID-19
VACCINATION AND BREASTFEEDING

29. • ICMR is currently doing a project on “Severity of COVID disease and
pregnancy outcome among women with COVID infection with or without
COVID vaccination – A multicentric case-control study”
• The study will be conducted in Govt. Medical colleges from 6 zones of the
country, namely JIPMER (South Zone), Lokamanya Tilak Municipal Medical
College in Mumbai (West Zone), AIIMS Bhubaneswar (East Zone), AIIMS
Bhopal (Central Zone), Maulana Azad Medical College (North Zone), and
Tripura Medical College (North-East Zone).
• I am contributing to this research project as I am the Principal Investigator of
the West Zone.

31. • This study, initiated on January 24, 2023, at LTMMC & Sion Hospital,
encompasses both retrospective and prospective analyses.
• A total of 104 cases of COVID-19 positivity were examined, with 19 identified
as severe.
• Among the severe cases, all 19 individuals were unvaccinated, resulting in
the unfortunate loss of six lives.
• This illustrates the crucial role that vaccines play in safeguarding lives.

32. TAKE HOME MESSAGE
• Vaccination stands as a cornerstone for preventing infectious diseases and
promoting well-being worldwide.
• Collaborative efforts across nations, communities, and healthcare systems are
paramount to overcome challenges and ensure universal immunization coverage.
• As we embark on this journey, let us unite to build a healthier, more resilient
world, where the benefits of immunization reach every corner, leaving no one
behind in our quest for a safer and healthier future.

35. REFERENCES
• Gardasil 9 (Human papillomavirus 9-valent vaccine, recombinant. US FDA
approved product information; Whitehouse Station, NJ: Merck & Co, Inc. June
2020.
• Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and
immunogenicity of VGX-3100, a therapeutic synthetic DNAccine targeting human
papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia
2/3: a randomised, double-blind, placebo-controlled phase 2b trial.Lancet 2015;
386:2078.
• Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human
papillomavirus. Emerg InfectDis 2003; 9:37.
• Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-
effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;
96:604.

36. Thank You…